Explore the vast range of titles available.

Breast Cancer (BC) is the most common cause of cancer-associated deaths in females worldwide. Despite advancements in BC treatment driven by extensive characterization of its molecular hallmarks, challenges such as drug resistance, tumor relapse, and metastasis persist. Therefore, there is an urgent need for alternative treatment approaches with multi-modal efficacy to overcome these hurdles. In this context, natural bioactives are increasingly recognized for their pivotal role as anti-cancer compounds. This study focuses on predicting molecular targets for key herbal phytoconstituents—gallic acid, piperine, quercetin, resveratrol, and beta-sitosterol—present in the polyherbal formulation, Krishnadi Churna. Using an in-silico network pharmacology model, key genes were identified and docked against these marker compounds and controls. Mammary carcinoma emerged as the most significant phenotype of the putative targets. Analysis of an online database revealed that out of 135 predicted targets, 134 were mutated in breast cancer patients. Notably, ESR1, CYP19A1, and EGFR were identified as key genes which are known to regulate the BC progression. Docking studies demonstrated that the herbal phytoconstituents had similar or better docking scores than positive controls for these key genes, with convincing protein-ligand interactions confirmed by molecular dynamics simulations, MM/GBSA and free energy landscape (FEL) analysis. Overall, this study highlights the predictive potential of herbal phytoconstituents in targeting BC genes, suggesting their promise as a basis for developing new therapeutic formulations for BC.

The Ayush sector has attained buoyant growth in the past decade as a science, public health, medicine, and industry. Artificial Intelligence, computational drug designing, and other combinatorial techniques could further accelerate the sector's growth. In this edition, we delve into the confluence of Ayurveda and technology, a theme that resonates profoundly in the contemporary healthcare and wellness landscape. The fusion of Ayurveda, an ancient system of medicine rooted in holistic well-being, with cutting-edge technology, is not just a paradigm shift but a necessary evolution in pursuing an integrated healthcare system where all systems have their defined, recognized, and respected contribution. Here, We are highlight one-such fusion initiative \"Ayurinformatics Laboratory\". [Display omitted]

Globally, the psychological health of the people is being affected due to the COVID-19 pandemic. Given the fact that numerous systematic reviews already exist on yoga and mental health, it becomes vital to undertake an overview on the same. The objective of the overview was to summarise the evidence from different systematic reviews of distinct yoga interventions used to improve mental health and recommend yoga practices for the same. The protocol was registered on PROSPERO (CRD42020185221). MEDLINE via Pubmed, Cochrane Database of Systematic Reviews and Google Scholar were searched for relevant literature. Search terms used were “Yoga practice, mental health and systematic review”. Reviews from earliest possible date till May 2020, including those examining the effects of any single or combination of yoga interventions on mental health reported on children, youth and adults were selected. The Assessment of Multiple Systematic Reviews (AMSTAR) tool was used to evaluate the evidence of the included reviews. Out of the 90 reviews found, eight unique reviews were selected for the overview. Overall, 243 studies were analyzed, with an overlap of only 6 studies across the reviews. Out of 8 reviews, only 2 were of high quality and the rest were of moderate quality. Owing to heterogeneity of the included studies, only descriptive analysis was possible. The results of the review indicate moderate to positive effects of yoga on the mental health parameters. Practicing yoga (physical postures, Bhramary Pranayam, mindfulness meditation, sahaj yoga and laughter therapy) can be beneficial to improve psychological health of the people during the COVID-19 pandemic.

Materiovigilance is regulatory system to study and follow incidents that might result from using medical devices. To trail the occurrence of untoward effects associated with medical devices as well as to document and prevent their recurrence; the Indian Pharmacopeia Commission initiated Materiovigilance program in India (MvPI) in 2015. Classical texts of Ayurveda include substantial description of devices intended for various therapeutic purposes such as Panchakarm (penta-bio purification procedures), Surgeries and for management of gynecological conditions etc. The implemented program of Materiovigilance does not include Ayurveda devices and thus there is need for documentation, systematic classification of Ayurveda devices and development of Ayurveda Materiovigilance (AMv). In this review, relevant information from classical texts of Ayurveda, latest published information related to Materiovigilance and information of medical devices from classical texts of Ayurveda has been scrutinized along with systematic correlation and applied interpretation of the collected data. It is observed that Materiovigilance has been well documented in Ayurveda in context of twenty six surgical and diagnostic devices; eleven mostly utilized pharmaceutical instruments five Panchakarma instruments and five home devices. For regulation of quality of Ayurveda medical devices, their manufacturing, standard utilization, reporting and prevention of medical device associated errors; it is the need of hour to create and implement regulation in the form of AMv. The Ayurveda literature highlights that the ancient seers of Ayurveda were well aware regarding Materiovigilance in their own way. However in view of modern era and mainstreaming of Ayurveda heritage, critical revision, updating, systematically categorization of Ayurveda devices, development and implementation of AMv regulation is the need of hour.

Background SARS-CoV-2 infections caused mild-to-moderate illness. However, a sizable portion of infected people experience a rapid progression of hyper-inflammatory and hypoxic respiratory illness that necessitates an effective and safer remedy to combat COVID-19. Methods A total of 150 COVID-19-positive patients with no to mild symptoms, between the age groups 19–65 years were enrolled in this randomized, open-labeled three-armed clinical trial. Among them, 136 patients completed the study with RT-PCR negative reports. The patients received herbal drugs orally (Group A ( Adhatoda vasica ; AV; 500 mg; n  = 50); Group B ( Tinospora cordifolia ; TC; 500 mg; n  = 43), and Group C (AV + TC; 250 mg each; n  = 43)) for 14 days. Clinical symptoms, vital parameters, and viral clearance were taken as primary outcomes, and biochemical, hematological parameters, cytokines, and biomarkers were evaluated at three time points as secondary outcomes. Results We found that the mean viral clearance time was 13.92 days (95% confidence interval [CI] 12.85–14.99) in Group A, 13.44 days (95% confidence interval [CI] 12.14–14.74) in Group B, and 11.86 days (95% confidence interval [CI] 10.62–13.11) days in Group C. Over a period of 14 days, the mean temperature in Groups A, and B significantly decreased linearly. In Group A, during the trial period, eosinophils, and PT/INR increased significantly, while monocytes, SGOT, globulin, serum ferritin, and HIF-1α, a marker of hypoxia reduced significantly. On the other hand, in Group B hsCRP decreased at mid-treatment. Eosinophil levels increased in Group C during the treatment, while MCP-3 levels were significantly reduced. Conclusions All the patients of the three-armed interventions recovered from COVID-19 and none of them reported any adverse effects from the drugs. Group C patients (AV + TC) resulted in a quicker viral clearance as compared to the other two groups. We provide the first clinical report of AV herbal extract acting as a modifier of HIF-1α in COVID-19 patients along with a reduction in levels of ferritin, VEGF, and PT/INR as the markers of hypoxia, inflammation, and thrombosis highlighting the potential use in progression stages, whereas the TC group showed immunomodulatory effects. Trial registration Clinical Trials Database -India (ICMR-NIMS), CTRI/2020/09/028043. Registered 24th September 2020, https://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=47443&EncHid=&modid=&compid=%27,%2747443det%27 Graphical Abstract

BackgroundLong covid describes a syndrome of persistent symptoms following COVID-19 and is responsible for substantial healthcare and economic burden. Currently, no effective treatments have been established. Ashwagandha (Withania somnifera (L.) Dunal) is a medicinal herb traditionally used in India for its immune-strengthening and anti-inflammatory properties. Withanolides, a family of steroid-derived molecules unique to Ashwagandha, have been shown to modulate inflammatory pathways in animal models, and several small randomised trials in humans support its effectiveness for reducing symptoms that are also associated with long covid. Therefore, this study aims to assess whether Ashwagandha is effective and safe for improving functional status and reducing symptom burden in adults living with long covid.MethodsA randomised double-blind placebo-controlled trial will be performed at participating general practice (GP) surgeries and long covid clinics across the UK. Individuals diagnosed with long covid will be screened for eligibility and then randomised 1:1 to take 1000 mg daily of Ashwagandha root extract tablets (standardised to <0.9% withanolides) or matching placebo tablets for 3 months (target, n = 2500). Monthly online surveys will be performed to collect patient-reported outcomes, and monthly safety monitoring, including liver function tests, will be conducted by clinical site teams. The primary outcome of the Post-COVID Functional Status Scale score at 3 months will be assessed by baseline-adjusted ordinal logistic regression, according to a pre-published statistical analysis plan. The secondary outcomes included validated quality of life and long covid symptom scales, work status and productivity and adverse events. The trial has been approved as a Clinical Trial of an Investigational Medicinal Produce by the Medicines and Healthcare Regulatory Authority and by the NHS Research Ethics Committee and Health Research Authority.DiscussionTreatments for long covid are urgently needed. This trial will robustly evaluate the safety and efficacy of a candidate treatment with a promising efficacy and safety profile. If found to be effective, the findings will likely influence treatment guidelines and improve health outcomes in those living with long covid.Trial registration numberThis trial was pre-registered on 15/08/2022: ISRCTN12368131

Anxiety disorders are among the most prevalent psychiatric conditions worldwide, yet the search for reliable biomarkers remains inconclusive. While modern biomedicine emphasizes measurable parameters such as cortisol, inflammatory cytokines, neurotransmitters, and neuroimaging indices, Ayurveda employs functional diagnostic constructs including dosha imbalance and manovaha srotas (∼Psychochannels) dysfunction. Though differing in language, both systems aim to identify markers that reflect underlying systemic dysregulation. This review adopted a comparative framework. Classical Ayurvedic texts (Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya) and modern indexed literature on biomarkers of anxiety were systematically analysed. Ayurvedic qualitative markers were mapped to modern physiological and biochemical indicators. Observational parallels and therapeutic implications were evaluated, with emphasis on translational integration. Ayurvedic constructs correlated significantly with modern biomarkers. Vata aggravation paralleled autonomic dysregulation and reduced heart rate variability. Rajas and tamas predominance aligned with catecholaminergic hyperactivity and prefrontal cortical hypoactivity. Ojas depletion reflected reduced brain-derived neurotrophic factor and altered cortisol rhythms, while ama accumulation resonated with elevated inflammatory cytokines (IL-6, TNF-α, CRP). Dysfunction of manovaha srotas corresponded to amygdala hyperactivity and impaired prefrontal–amygdala connectivity. Therapeutic interventions including Withania somnifera, Bacopa monnieri, yoga, and meditation demonstrated measurable effects on cortisol, HRV, GABA, and inflammatory markers, complementing conventional therapies. Ayurveda provides systemic, functional biomarkers, while modern biomedicine contributes quantifiable indices. Their integration offers a multidimensional framework for understanding and managing anxiety disorders. This conceptual bridge highlights the potential for developing hybrid biomarker models that enhance diagnosis, monitoring, and personalized treatment.

India has systematically integrated Indian traditional medicine systems Ayurveda, Yoga, Unani, Siddha, Sowa-rigpa including Homeopathy -collectively known as 'Ayush' into its public healthcare delivery. Since upgrading the Department of Ayush to a dedicated Ministry of Ayush in the year 2014, several landmark initiatives have been launched, including the National Ayush Mission (NAM), the establishment of Ayush Health and Wellness Centres under Ayushman Bharat, and the creation of the Ayushman Arogya Mandirs network. These efforts reflect a strategic commitment to enhance primary health care (PHC) by promoting culturally relevant, preventive, and affordable services. This practice and policy review employed a systematic approach to analyze the integration of Ayush into India's PHC system. Primary and secondary source of data was drawn from national health policies, government reports, international frameworks, and official statistics between 2014 and 2024. Data was analyzed in detail to assess implementation status, infrastructure, global positioning, education, digital integration, and policy challenges. India's traditional medicine sector includes 12,500 Ayushman Arogya Mandir led by qualified doctors of Ayurveda, Unani, Siddha, Sowarigpa and homeopathy doctors, 750,000 registered institutionally qualified practitioners, more than 700 Ayush medical colleges and attached hospitals, around 9,000 Ayush drug manufacturing industries, dedicated research councils for ewach of the Ayush system with their peripheral centers, a Pharmacopoeia Commission of Indian systems of Medicine and Homeopathy etc. Moreover, Ayush systems are integrated in 26,636 Primary Health Centres (PHCs), 6,155 Community Health Centres (CHCs), and 759 Districts Hospitals (DH) in the country. Ayush systems are also integrated in health infrastructure under Ministry of Defense, Ministry of Labour Welfare, Ministry of Railways etc. Public health programs targeting maternal health, geriatric care, and non-communicable diseases have incorporated Ayush-based approaches. Internationally, India has established academic collaborations and information cells across 42 countries and academic chairs across 38 countries, while domestic initiatives focus on digital health (Ayush Grid), education reform (NEP 2020), quality assurance, and cross-referral pathways. India's integrative approach demonstrates how traditional medicine can enhance PHC delivery, particularly in underserved settings. With continued investment in evidence-based practices, regulatory alignment, and inclusive models, Ayush can play a pivotal role in achieving Universal Health Coverage and informing global traditional medicine strategies.

AIAPGET 2019, an all India ranking entrance Test for MD/MS courses of Ayurveda, Unani, Siddha and Homeopathy stream was conducted by joint collaboration of National Testing Agency (NTA) and All India Institute of Ayurveda (AIIA). In this article, we present the item analysis of AIAPGET 2019 Ayurveda stream MCQs. The aim of this article was to analyse the MCQs of AIAPGET 2019 of Ayurveda stream. This exam was computer based conducted all over 25 centers across India. The question paper had 100 MCQs with 1 correct answer and 3 distractors for each item (Problem statement). AIAPGET 2019 question paper of Ayurveda stream had a Difficulty index of 37.32 ± 16.11 Discriminatory Index of 0.46 ± 0.27 and Distractor Index of 89 ± 17.8. Our analysis showed that though ideal, the question paper trended towards difficulty side.